Journal Article (Review Article)

DZNE-2022-00138

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder

Miglis, M. G. ; Adler, C. H. ; Antelmi, E. ; Arnaldi, D. ; Baldelli, L. ; Boeve, B. F. ; Cesari, M. ; Dall'Antonia, I. ; Diederich, N. J. ; Doppler, K. ; Dušek, P. ; Ferri, R. ; Gagnon, J.-F. ; Gan-Or, Z. ; Hermann, W.DZNE* ; Högl, B. ; Hu, M. T. ; Iranzo, A. ; Janzen, A. ; Kuzkina, A. ; Lee, J.-Y. ; Leenders, K. L. ; Lewis, S. J. G. ; Liguori, C. ; Liu, J. ; Lo, C. ; Ehgoetz Martens, K. A. ; Nepozitek, J. ; Plazzi, G. ; Provini, F. ; Puligheddu, M. ; Rolinski, M. ; Rusz, J. ; Stefani, A. ; Summers, R. L. S. ; Yoo, D. ; Zitser, J. ; Oertel, W. H.Extern*

2021
Lancet Publ. Group London

This record in other databases:    

Please use a persistent id in citations: doi:10.1016/S1474-4422(21)00176-9

Abstract: Patients with isolated rapid-eye-movement sleep behaviour disorder (RBD) are commonly regarded as being in the early stages of a progressive neurodegenerative disease involving α-synuclein pathology, such as Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy. Abnormal α-synuclein deposition occurs early in the neurodegenerative process across the central and peripheral nervous systems and might precede the appearance of motor symptoms and cognitive decline by several decades. These findings provide the rationale to develop reliable biomarkers that can better predict conversion to clinically manifest α-synucleinopathies. In addition, biomarkers of disease progression will be essential to monitor treatment response once disease-modifying therapies become available, and biomarkers of disease subtype will be essential to enable prediction of which subtype of α-synucleinopathy patients with isolated RBD might develop.

Keyword(s): Biomarkers (MeSH) ; Disease Progression (MeSH) ; Humans (MeSH) ; Prognosis (MeSH) ; REM Sleep Behavior Disorder: complications (MeSH) ; REM Sleep Behavior Disorder: diagnosis (MeSH) ; Synucleinopathies: diagnosis (MeSH) ; Synucleinopathies: etiology (MeSH) ; alpha-Synuclein (MeSH)

---

Contributing Institute(s):

1. Clinical Dementia Research (Rostock /Greifswald) (AG Teipel)

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

Appears in the scientific report 2021

---

Database coverage:
; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 50 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---